Search the Newsreel

LifeStance Health Surpasses Q2 Earnings Expectations Driven by Clinician Growth

LifeStance Health significantly exceeded Q2 earnings expectations, reporting $435.4 million in revenue and an adjusted EPS of $0.11, driven by a 26.1% year-over-year growth and improved operational efficiency. The company raised its full-year guidance for both revenue and EBITDA, reflecting strong management confidence. This …

LifeStance Health Group (NASDAQ:LFST) Given New $13.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for LifeStance Health Group (NASDAQ:LFST) to $13.00 from $9.00, while maintaining a "neutral" rating. This new target implies a potential upside of 2.48% from the stock's previous close. The company recently reported strong quarterly earnings, …

LifeStance Health Group (LFST) Turned Profitable And Lifted Guidance, Is It Still Below Fair Value?

LifeStance Health Group (LFST) Is Up 3.44% in One Week: What You Should Know

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …

LifeStance Health Group, Inc. SEC Filing (Aug 13, 2026)

This article reports on a Form 144 SEC filing by LifeStance Health Group, Inc. (LFST) on August 13, 2026. The filing indicates a proposed sale of 20,441 shares of common stock with an aggregate market value of $249,993.43 by an unnamed person through Fidelity …

Zacks.com featured highlights include LifeStance Health, Tutor Perini, Valero Energy, SharkNinja and Lumentum

For Immediate Release Chicago, IL – August 13, 2026 – Stocks in this week's article are LifeStance Health Group LFST, Tutor Perini TPC, Valero Energy VLO, SharkNinja, Inc. SN and Lumentum LITE. 5 Low-Leverage Stocks to Buy as High Oil Prices Shake Investor Confidence …

5 Insightful Analyst Questions From LifeStance Health Group’s Q2 Earnings Call

LifeStance Health Group (LFST) exceeded Q2 earnings expectations with strong clinician productivity and specialty service expansion, prompting a raised full-year guidance. Analysts questioned management on productivity gains, revenue per visit drivers, EHR rollout, M&A strategy, and sequential EBITDA guidance, receiving insights into the company's …

LifeStance Health Group (NASDAQ:LFST) Major Shareholder Tpg Gp A, Llc Sells 13,643,207 Shares

Major shareholder Tpg Gp A, Llc sold over 13.6 million shares of LifeStance Health Group (NASDAQ:LFST) for approximately $144.9 million, reducing their stake by 12.21%. This transaction follows LifeStance's strong quarterly performance, which saw an EPS beat and 26.1% year-over-year revenue growth, pushing the …

LifeStance CTO Vukasin Paunovich sells $481,674 in stock

LifeStance Health Group's CTO, Vukasin Paunovich, sold 44,394 shares worth $481,674 on August 10, 2026. This sale occurred after the stock surged 147% over the past year, trading 13% higher than the sale price. The company recently reported strong Q2 2026 financial results, exceeding …

LifeStance Health Group (LFST) Stock Looks Strong On Returns Yet Stretched On Earnings

LifeStance Health Group (LFST) Is Up 12.1% After Profit Turn, Higher Guidance And New Buyback Program

LifeStance Health Group (LFST) reported strong second-quarter results with higher sales and a move to net profitability, leading to a 12.1% increase in its stock. The company also raised its 2026 revenue outlook to about US$1.71 billion, completed a US$97.19 million share repurchase, and …

LifeStance Health Group Inc (LFST) Shares Fall 3.4% -- GF Value Says Still Overvalued

LifeStance Health Group Inc (LFST) shares dropped 3.4% to $11.50, but according to GuruFocus' GF Value, the stock is still 35.8% overvalued with a GF Value of $8.47. The company's GF Score is 55/100, indicating average performance with strong financial strength but poor profitability …

LifeStance Health (LFST) holder files to sell 500,000 common shares via Fidelity

A holder of LifeStance Health (LFST) common stock has filed a Form 144 to sell up to 500,000 shares through Fidelity Brokerage Services LLC, with an aggregate market value of over $5.7 million. These shares primarily originate from restricted stock vesting events tied to …

Summit Partners group (LFST) discloses 6.10% LifeStance Health ownership in 13G/A

A group of Summit Partners-affiliated investment funds has filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.10% in LifeStance Health Group, Inc. (LFST). This stake amounts to 23,310,115 shares of common stock out of 382,055,609 shares outstanding as of July 29, …

LifeStance Health (LFST) Upgraded to Buy: Here's Why

LifeStance Health Group (LFST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A …

LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out?

LifeStance Health Group (LFST) has reached a new 52-week high, with shares up 9.4% in the past month and 69% year-to-date. The company has consistently beaten earnings estimates, reporting 600% EPS growth for the current fiscal year. Despite concerns about its high valuation metrics …

One in Three Women Unaware Perimenopause Can Cause Mental Symptoms

A LifeStance Health survey found that one in three women are unaware that perimenopause can cause mental health symptoms, despite a majority experiencing severe anxiety and depression. The survey revealed that 83% of women who tried therapy found it helpful, and nearly half believe …

LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care

A new survey by LifeStance Health reveals that a significant number of women are unaware of the mental health impact of perimenopause, with one in three not knowing it can cause anxiety, depression, and mood changes. The survey highlights that while most women find …

LifeStance Health Group (LFST) holder cites pre-IPO shares in planned resale

Citadel Securities LLC has filed a Form 144 notice regarding the planned resale of 21,572 shares of LifeStance Health Group (LFST) common stock. These shares were acquired through pre-IPO transactions on June 10, 2021. The filing also notes that Citadel sold 1,273 LifeStance shares …

How Investors Are Reacting To LifeStance Health Group (LFST) Profit Return, Guidance Hike, And New Buyback

LifeStance Health Group (LFST) investor plans NASDAQ sale of 12,165 shares

A stockholder of LifeStance Health Group Inc. (LFST) plans to sell 12,165 shares of common stock on NASDAQ through Citadel Securities LLC. The proposed sale, valued at $129,192.30, is scheduled for August 10, 2026. The seller had previously acquired 206,219 equity interests in LifeStance …

LifeStance Health (LFST) Form 144 shows planned sale of 1.09M shares

LifeStance Health Group Inc. has filed a Form 144 indicating a proposed resale of 1,088,162 shares of its common stock, with an aggregate market value of $11,556,280.44. The shares are scheduled to be sold on or after August 10, 2026, on NASDAQ through Citadel …

LifeStance Health Group, Inc. SEC Filing (Aug 10, 2026)

This article reports on a Form 144 SEC filing by LifeStance Health Group, Inc. (LFST) on August 10, 2026. The filing indicates a proposed sale of 44,394 shares of common stock acquired through restricted stock vesting on March 9, 2026, with an aggregate market …

LifeStance Health Group Surges 13.0% Amid Sector-Wide Rally

LifeStance Health Group (NASDAQ:LFST) surged 13.0% to $12.25, leading a broad rally in the medical care facilities sector. This sector-wide movement, which also saw RDNT climb 6.8% and BLLN gain 4.7%, indicates investor enthusiasm potentially driven by optimism about industry fundamentals or macroeconomic tailwinds. …

LifeStance Health Group (NASDAQ:LFST) Reaches New 1-Year High After Analyst Upgrade

LifeStance Health Group (NASDAQ:LFST) shares hit a new 52-week high after BTIG Research raised its price target from $15 to $16, maintaining a buy rating. The company exceeded quarterly expectations with adjusted earnings of $0.06 per share and revenue up 26.1% year-over-year. Despite favorable …

Lifestance Health Group Inc stock hits 52-week high at 11.77 USD

Lifestance Health Group Inc (LFST) stock reached a 52-week high of $11.77, trading near its peak valuation with a market capitalization of $4.35 billion. Despite being considered slightly overvalued by InvestingPro, the stock has seen a 148% increase over the past year and reported …

LifeStance Health gains as Hedgeye adds as new long idea

LifeStance Health (LFST) shares surged by 14% after Hedgeye identified it as a new long idea, projecting a potential upside of 32-60%. Hedgeye analyst Tom Tobin noted that the company's core business is outperforming consensus expectations across all three key revenue drivers.

LFST Q2 Deep Dive: Margin Expansion and Specialty Services Propel Growth Outlook

LFST Q2 Deep Dive: Margin Expansion and Specialty Services Propel Growth Outlook Behavioral health company LifeStance Health (NASDAQ:LFST) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 26.1% year on year to $435.4 million. Guidance for next quarter's revenue was …

LifeStance Health Group (NASDAQ:LFST) Releases Earnings Results, Beats Expectations By $0.03 EPS

Renaissance Technologies LLC Has $5.10 Million Stake in LifeStance Health Group, Inc. $LFST

Renaissance Technologies LLC significantly increased its stake in LifeStance Health Group (LFST) by 92.5% in the first quarter, now holding 800,500 shares valued at $5.1 million. LifeStance reported strong Q2 results, with revenue up 26.1% year-over-year and adjusted earnings beating estimates, leading to a …

LifeStance Health Group (LFST) Stock Faces Valuation Questions After Margin Breakthrough

LifeStance Health Group, Inc. Q2 2026: Revenue $435.4M, EPS $0.06— 10-Q Summary

LifeStance Health Group, Inc. reported strong Q2 2026 results, with revenue increasing to $435.4M from $345.3M year-over-year, and net income turning profitable at $23.6M compared to a loss of $3.8M in Q2 2025. Diluted EPS reached $0.06, up from $(0.01) in the prior-year quarter. …

LifeStance Health Group, Inc. Stock 12‑Month Price Target Raised to $12.6, Implies 22% Upside

LifeStance Health Group, Inc.'s average price target has been increased from $12 to $12.6 by 10 analysts, suggesting a 22% potential upside from its Aug. 5 closing price. The consensus rating for the stock remains a "Buy" across 11 analysts, with 9 recommending Buy …